Guy Cavet
YOU?
Author Swipe
View article: Fragment correlation mass spectrometry: Determining the structures of biopolymers in a complex mixture without isolating individual components
Fragment correlation mass spectrometry: Determining the structures of biopolymers in a complex mixture without isolating individual components Open
Fragment correlation mass spectrometry correlates ion pairs generated from the same fragmentation pathway, achieved by covariance mapping of tandem mass spectra generated with an unmodified linear ion trap without preseparation. We enable …
View article: Fragment correlation mass spectrometry enables direct characterization of di-sulfide cleavage pathways of therapeutic peptides
Fragment correlation mass spectrometry enables direct characterization of di-sulfide cleavage pathways of therapeutic peptides Open
Therapeutic peptides that are connected by disulfide bonds are often difficult to analyze by traditional tandem mass spec-trometry without chemical modification. Using fragment correlation mass spectrometry, we measured 56 pairs of fragmen…
View article: A candidate antibody drug for prevention of malaria
A candidate antibody drug for prevention of malaria Open
Over 75% of malaria-attributable deaths occur in children under the age of 5 years. However, the first malaria vaccine recommended by the World Health Organization (WHO) for pediatric use, RTS,S/AS01 (Mosquirix), has modest efficacy. Compl…
View article: A candidate antibody drug for prevention of malaria.
A candidate antibody drug for prevention of malaria. Open
Plasmablast human antibody repertoire sequences from volunteers in a malaria vaccine (RTS,S) clinical trial with sequence and donor annotations
View article: A candidate antibody drug for prevention of malaria.
A candidate antibody drug for prevention of malaria. Open
Plasmablast human antibody repertoire sequences from volunteers in a malaria vaccine (RTS,S) clinical trial with sequence and donor annotations
View article: An antibody drug engineered for prevention of malaria in global populations
An antibody drug engineered for prevention of malaria in global populations Open
Over 80% of malaria-attributable deaths are in children under five. However, the only malaria vaccine recommended by the World Health Organization (WHO) for paediatric use, Mosquirix™, has limited efficacy. Complementary strategies, like m…
View article: Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Breast cancers can be divided into subtypes with important implications for prognosis and treatment. We set out to characterize the genetic alterations observed in different breast cancer subtypes and to identify specific candidate genes a…
View article: Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
View article: Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain Open
Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
View article: Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
View article: Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain Open
Although activating mutations and gains in copy number are key mechanisms for oncogene activation, the relationship between the two is not well understood. In this study, we focused on KRAS copy gains and mutations in non–small cell lung c…
View article: Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
View article: Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Breast cancers can be divided into subtypes with important implications for prognosis and treatment. We set out to characterize the genetic alterations observed in different breast cancer subtypes and to identify specific candidate genes a…
View article: Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain Open
Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
View article: Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain Open
Although activating mutations and gains in copy number are key mechanisms for oncogene activation, the relationship between the two is not well understood. In this study, we focused on KRAS copy gains and mutations in non–small cell lung c…
View article: Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Open
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
View article: Supplementary Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Supplementary Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
Supplementary Data from In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
View article: Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: Data from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Data from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
The insulin-like growth factor-I receptor (IGF-IR) pathway is required for the maintenance of the transformed phenotype in neoplastic cells and hence has been the subject of intensive drug discovery efforts. A key aspect of successful clin…
View article: CCR Translation for the Article from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
CCR Translation for the Article from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
CCR Translation for the Article from In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
View article: Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
Purpose: The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidyl…
View article: Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Supplementary Table 1 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: CCR Translation for the Article from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
CCR Translation for the Article from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
CCR Translation for the Article from In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
View article: Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
Purpose: The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidyl…
View article: Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
Commentary on this Article from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
View article: Supplementary Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Supplementary Data from <i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Open
Supplementary Data from In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
View article: Data from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Data from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Open
The insulin-like growth factor-I receptor (IGF-IR) pathway is required for the maintenance of the transformed phenotype in neoplastic cells and hence has been the subject of intensive drug discovery efforts. A key aspect of successful clin…